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ABSTRACT 
Cardiac fibroblasts (CF) play a pivotal role in the repair and remodeling of the heart that 
occurs following myocardial infarction (MI). The transition through the inflammatory, 
granulation and maturation phases of infarct healing is driven by cellular responses to local 
levels of cytokines, chemokines and growth factors that fluctuate in a temporal and spatial 
manner. In the acute inflammatory phase early after MI, CF contribute to the inflammatory 
milieu through increased secretion of proinflammatory cytokines and chemokines, and they 
promote extracellular matrix (ECM) degradation by increasing matrix metalloproteinase 
(MMP) expression and activity. In the granulation phase, CF migrate into the infarct zone, 
proliferate and produce MMPs and pro-angiogenic molecules to facilitate revascularization. 
Fibroblasts also undergo a phenotypic change to become myofibroblasts. In the maturation 
phase, inflammation is reduced by anti-inflammatory cytokines, and increased levels of 
profibrotic stimuli induce myofibroblasts to synthesize new ECM to form a scar. The scar is 
contracted through the mechanical force generated by myofibroblasts, preventing cardiac 
dilation. In this review we discuss the transition from myocardial inflammation to fibrosis 
with particular focus on how CF respond to alterations in proinflammatory and profibrotic 
signals. By furthering our understanding of these events, it is hoped that new therapeutic 
interventions will be developed that selectively reduce adverse myocardial remodeling post-
MI, whilst sparing essential repair mechanisms.    
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1. Introduction 
Myocardial infarction (MI)
1
 results from ischaemia of an area of myocardial tissue subserved 
by an occluded coronary artery. The consequent injury and death of cardiomyocytes triggers 
an acute inflammatory response that initiates the repair of the myocardium through a series of 
well orchestrated events (summarized in Fig. 1 and Fig. 2). The inflammatory phase is 
associated with rapid local increases in proinflammatory cytokines and chemokines, such as 
interleukin (IL)-1, IL-6, IL-8 and tumor necrosis factor  (TNF), and neutrophil infiltration 
(Frangogiannis et al., 2002; Frangogiannis and Entman, 2005). Cardiac fibroblasts (CF) are 
the most prevalent resident myocardial cell type, accounting for up to two-third of heart cells 
(Porter and Turner, 2009). Although traditionally known for being essential regulators of 
extracellular matrix (ECM) remodeling, it is becoming increasingly apparent that CF play a 
central role in many aspects of post-MI remodeling of the heart (Porter and Turner, 2009). 
Recent evidence suggests that CF may contribute to the early inflammatory phase of 
remodeling by secreting several important proinflammatory cytokines and chemokines 
(Turner et al., 2009; Turner et al., 2010; Turner et al., 2011). 
 Approximately 3 days after MI, the infarct area is infiltrated by macrophages and 
phenotypically modified fibroblasts (myofibroblasts), that form granulation tissue in which 
ECM-degrading proteases of the matrix metalloproteinase (MMP) family and pro-angiogenic 
molecules such as vascular endothelial growth factor (VEGF) are up-regulated (Jourdan-
Lesaux et al., 2010; Lindsey and Zamilpa, 2012). The granulation stage of remodeling is 
characterized by the clearance of dead cells, the breakdown of ECM and stimulation of 
angiogenesis to revascularize the ischemic tissue. 
 Transition from the inflammatory phase to the fibrotic stage of remodeling 
(“maturation”) typically occurs 3-7 days post-MI depending on the species (Dewald et al., 
2004) and appears to be mediated by increased production of anti-inflammatory and 
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profibrotic factors such as transforming growth factor- (TGF) and IL-10, derived from 
both infiltrating immune cells and myocardial cells. In response to such factors, 
myofibroblasts synthesize increased amounts of structural ECM proteins, particularly type I 
and III fibrillar collagens, to facilitate scar formation. This response is essential to replace the 
areas devoid of cardiomyocytes and prevent rupture of the myocardial wall. Balanced ECM 
remodeling is crucial, since inadequate strength of the myocardial wall will lead to cardiac 
dilation, while excessive or prolonged ECM accumulation can result in fibrosis. While 
cardiac dilation primarily affects systolic function, fibrosis stiffens the myocardium and 
mainly hampers the diastolic filling phase.  
 Myofibroblasts express increased levels of contractile proteins such as alpha-smooth 
muscle actin (SMA), vimentin and focal adhesion proteins that permit them to contract the 
scar area to enable effective wound healing (van den Borne et al., 2010). In contrast to wound 
healing in other tissues and organs (e.g. skin) in which the myofibroblasts are effectively 
removed from scar tissue by apoptosis, cardiac myofibroblasts appear to remain within the 
healed infarct area for many years (Palatinus et al., 2010; van den Borne et al., 2010). 
Whether myofibroblast persistence is beneficial or detrimental to the integrity of the healed 
infarct remains to be firmly established.  
 Effective infarct healing involves the coming together of both resident and infiltrating 
cell types in a highly spatially and temporally coordinated manner. Given that infarct size is a 
major predictor of post-MI mortality (Burns et al., 2002), the transition from the early 
inflammatory phase of remodeling (which increases infarct area) to the fibrotic maturation 
phase of remodeling (which limits infarct expansion) is paramount for effective healing and 
reduced secondary complications. This review focuses on the key role played by CF in this 
transition.     
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2. Cardiac fibroblasts 
Under normal physiological conditions, CF are relatively inert cells that maintain myocardial 
ECM homeostasis. However, in response to cardiac injury or stress, CF can adopt a 
specialized myofibroblast phenotype (van den Borne et al., 2010) that enables the cells to 
respond more effectively to environmental stimuli. This phenotypic plasticity of fibroblasts in 
the heart allows them to migrate into the infarcted area in response to chemotactic stimuli, 
proliferate in response to mitogenic factors, and differentiate into myofibroblasts that drive 
aggressive remodeling of the ECM and wound contraction, enabling rapid and effective 
repair of the cardiac interstitium (see Fig. 2). 
 Very recently, reprogramming of cardiac fibroblasts into functional cardiomyocytes 
using specific transcription factors or micro-RNAs was reported (Ieda et al., 2010; Qian et al., 
2012; Song et al., 2012; Jayawardena et al., 2012). This revolutionary technique holds great 
promise for replacing necrotic cardiomyocytes following MI by generating functional cardiac 
muscle tissue from resident CF. If applicable after human MI, this approach could reduce 
infarct size and adverse remodeling and improve cardiac functional recovery.   
 
2.1. Myofibroblast phenotype 
It has long been accepted that cardiac myofibroblasts can be derived from mature resident 
CF, but there is now increasing evidence that they can also originate from endothelial cells, 
epithelial cells, pericytes, circulating bone marrow-derived progenitor cells (fibrocytes) and  
mesenchymal stem cells (Carlson et al., 2011; Zeisberg et al., 2007; Keeley et al., 2010; 
Haudek et al., 2006). Irrespective of their origin, myofibroblasts are characterised by 
increased expression of specific contractile proteins (SMA, vimentin), focal adhesion 
proteins (paxillin, tensin, integrins), cell surface receptors (TRII, AT1R, Frizzled) and ECM 
proteins (collagen I, collagen III and the ED-A splice variant of fibronectin) (van den Borne 
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et al., 2010; Tomasek et al., 2002; Daskalopoulos et al., 2012). Many of these molecular 
changes confer increased tensile characteristics on the myofibroblast cell, allowing it to 
efficiently contract the surrounding ECM and facilitate effective post-MI scar formation and 
thinning (van den Borne et al., 2010; Tomasek et al., 2002).  
 The profibrotic cytokine TGF is considered to be the prime inducer of the mature 
myofibroblast phenotype (Dobaczewski et al., 2011; Tomasek et al., 2002). Other factors that 
contribute to myofibroblast differentiation include mechanical tension and ED-A fibronectin 
(Tomasek et al., 2002) and more recently, roles for Type VI collagen (Naugle et al., 2006) 
and Wnt/frizzled signaling (Laeremans et al., 2010) have been described in CF. Although not 
particularly well studied in the heart, there is evidence that TGF-induced differentiation of 
myofibroblasts from non-cardiac sources can be opposed by the action of proinflammatory 
cytokines, including IL-1 and TNF (Shephard et al., 2004; Liu et al., 2009). 
 Interestingly, when grown in vitro in rigid culture vessels, CF spontaneously undergo 
transition to a myofibroblast phenotype which is maintained or enhanced with passaging 
(Mughal et al., 2009; Santiago et al., 2010; Teunissen et al., 2007). This in vitro phenotype 
shares many similarities with that of myofibroblasts found in the infarct area in vivo 
(Santiago et al., 2010). In addition to enhanced contractile, focal adhesion and receptor 
proteins, cultured myofibroblasts are less motile than their fibroblast counterparts, reflecting 
a change from migratory to synthetic and contractile function (Santiago et al., 2010).  
   
2.2. Regulation of extracellular matrix turnover by cardiac fibroblasts 
CF regulate myocardial ECM turnover by balancing the synthesis and degradation of ECM 
components in response to physiological and pathophysiological stimuli. As the key source of 
ECM molecules in the heart, (myo)fibroblasts can synthesize a wide range of structural 
matrix proteins (e.g. fibrillar collagens, laminins, fibronectin), as well as matricellular 
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proteins; a group of ECM-regulatory proteins that includes connective tissue growth factor 
(CTGF/CCN2), thrombospondins, tenascins, osteopontin/SPP1 and osteonectin/SPARC 
(Frangogiannis, 2012). These matricellular proteins are extracellular proteins that do not 
serve structural roles, but rather modulate cell-matrix interaction and cellular function 
(Bornstein and Sage, 2002). For example, CCN2 can bind TGF1 and enhance its signaling 
activity (Abreu et al., 2002). 
 Conversely, CF are also a rich source of proteases, including the MMP family of 
enzymes that together are capable of degrading all the protein components of the myocardial 
ECM (Spinale, 2007). CF express several different MMPs, including MMP-1, -2, -3, -9 and -
14, and their expression and activation can be differentially modulated by various 
proinflammatory (e.g. IL-1, TNF) and profibrotic (e.g. TGF-, Ang II) stimuli (Turner and 
Porter, 2012). CF can further control the proteolytic activity of MMPs through regulating 
expression and secretion of TIMPs, the endogenous inhibitors of MMPs, with TIMP-1 and 
TIMP-2 being the major forms expressed by CF (Brown et al., 2007; Turner et al., 2010). 
Hence, by coordinating synthesis and activation of structural ECM proteins, matricellular 
proteins, MMPs and TIMPs, CF are able to precisely control myocardial ECM turnover, and 
help to compensate for impaired cardiac function following myocardial injury or stress.       
 
2.3. Cardiac fibroblasts as producers of autocrine/paracrine factors 
CF represent a rich local source of secreted bioactive molecules that can regulate the function 
of adjacent cells via autocrine/paracrine signaling networks. These factors include 
proinflammatory cytokines (e.g. TNF, IL-1 and IL-6), chemokines (e.g. CXCL1/GRO 
and CXCL8/IL-8), profibrotic factors (e.g. TGF, Ang II and endothelin-1) and molecules 
regulating neovascularization (e.g. VEGF and ADAMTS1) (Porter and Turner, 2009; Turner 
et al., 2009; Turner et al., 2010; Turner et al., 2011). By regulating the local concentrations of 
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such factors, CF are able to modulate not only their own function but that of other cell types 
(e.g. cardiomyocytes, inflammatory cells, endothelial cells) to coordinate the myocardial 
remodeling process.  
 
3. Cardiac fibroblast responses to proinflammatory and profibrotic stimuli 
3.1. Effect of proinflammatory stimuli on CF 
The levels of proinflammatory cytokines TNF and IL-1 increase rapidly in the infarcted 
myocardium (Frangogiannis et al., 2002; Ono et al., 1998). TNF may derive from mast cells 
(Gordon and Galli, 1990) or fibroblasts (Turner et al., 2009), while IL-1 could initially be 
released from necrotic cardiomyocytes (Chen et al., 2007).  
      The IL-1 family of cytokines includes IL-1 and IL-1 which have similar structure, 
bind to the same membrane receptors and apparently have indistinguishable biological 
activities (Bujak and Frangogiannis, 2009). In isolated human CF, IL-1 strongly stimulated 
the expression of the pro-inflammatory cytokines IL-1, TNF and IL-6, implicating CF as 
being important in mediating the post-MI inflammatory response (Turner et al., 2009). 
Furthermore, IL-1 enhanced the expression of several CXC chemokines and adhesion 
molecules important in neutrophil infiltration (Turner et al., 2011). A similar stimulatory 
effect on CF chemokine expression was also described for Oncostatin M, a member of the IL-
6 family of cytokines (Lafontant et al., 2006). Moreover, IL-1 induced MMP-1, MMP-3, 
MMP-9 and MMP-10, indicating that increased levels of this cytokine have important 
consequences for ECM degradation (Turner et al., 2010). Increased MMP expression and 
activity was also observed in rat CF stimulated by IL-1 (Brown et al., 2007) or TNF 
(Siwik et al., 2000). IL-1 and TNF reduced total collagen synthesis ([3H]-proline 
incorporation) in neonatal and adult rat CF suggesting these cytokines may contribute to 
ventricular dilation (Siwik et al., 2000; Xiao et al., 2008). However, we reported recently that 
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IL-1 had no direct effect on basal Type I collagen (COL1A1) mRNA expression in human 
CF measured after 6 h (Turner et al., 2010). In contrast, IL-1 markedly reduced CCN2 
mRNA expression at this early time point (Turner, 2011, unpublished data). It is feasible 
therefore that the longer-term reductions in collagen expression that were previously reported 
in response to IL-1-stimulated rat CF (Siwik et al., 2000; Xiao et al., 2008) are due to an 
indirect autocrine/paracrine mechanism involving reduced CCN2 expression. 
 IL-1 also acts on CF to modulate factors that are important for neovascularization of 
the ischemic area. Using a focused microarray approach, we identified ADAMTS1 as a gene 
whose expression was reduced in response to IL-1 stimulation in human CF (Turner et al., 
2010). ADAMTS1 is a secreted metalloproteinase that inhibits neovascularization through 
inhibition of VEGF signaling. Thus, by reducing ADAMTS1 expression and increasing 
VEGF expression at the level of the CF (Turner et al., 2010), IL-1 may promote angiogenesis 
in the infarcted myocardium. 
      Aside from the gene expression responses, IL-1 was shown to inhibit CF 
proliferation (Palmer et al., 1995) and enhance migration of these cells (Mitchell et al., 2007). 
By contrast, IL-33, another member of the IL-1 family, inhibited rat CF migration (Zhu and 
Carver, 2012). Surprisingly, in both studies similar signaling pathways (MAP kinase) were 
activated (Mitchell et al., 2007; Zhu and Carver, 2012). A further member of the IL-1 family, 
IL-18, was also shown to moderately increase CF migration and proliferation (Fix et al., 
2011). Very recently, IL-17A, belonging to a new family of cytokines, was reported to 
stimulate CF proliferation and migration (Valente et al., 2012). The net effect of the 
combination of these cytokines on CF proliferation and migration in vivo will be dependent 
on their relative abundance and activity in the remodeling myocardium.  
      Taken together, the above reports indicate that CF are actively involved in the 
inflammatory phase following MI by producing cytokines, chemokines and adhesion 
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molecules, and contributing to infiltration of immune cells. In addition, under the influence of 
IL-1-family inflammatory cytokines CF show increased MMP activity, which favors ECM 
degradation, remodeling and neovascularization. See Fig. 2 for summary. 
    
3.2. Effect of profibrotic stimuli on CF 
Various humoral factors including TGF, Ang II, CCN2/CTGF, basic fibroblast growth 
factor (bFGF), platelet-derived growth factor (PDGF), insulin-like growth factor-1 and 
catecholamines are important in cardiac fibrosis (Leask, 2010; Manabe et al., 2002; Nicoletti 
and Michel, 1999; Daniels et al., 2009). The best known and most studied pro-fibrotic 
stimulus in the heart is TGF. After MI, TGF is strongly induced, and it plays a central role 
in infarct healing and myocardial remodeling (Bujak and Frangogiannis, 2007; Leask, 2007; 
Lijnen et al., 2000). Mammals express three structurally similar isoforms of TGF (TGF1, 
TGF2 and TGF3). Although these isoforms are encoded by separate genes, and are thus 
expressed independently, they signal through the same cell surface receptors, and have 
identical downstream signaling effects. TGF1 is increased rapidly after MI and is highly 
expressed in the first week, while TGF3 shows a delayed induction and is strongly increased 
after 1 week (Dewald et al., 2004). TGF1 expression was found to remain elevated 4 weeks 
after MI (Chuva de Sousa Lopes SM et al., 2004; Sun et al., 1998). 
      Initially, TGF may play a role in suppressing cytokine expression in the infarct 
region, thereby inhibiting the inflammatory reaction. In the later phase, TGF is critical in 
differentiation of CF to myofibroblasts and de novo synthesis of ECM molecules essential for 
infarct healing (Bujak and Frangogiannis, 2007). The importance of TGF function in infarct 
healing was elegantly shown by TGFinhibition studies (Frantz et al., 2008). Anti-TGF-
antibodies administered after MI led to further left ventricular dilation and increased 
mortality (Frantz et al., 2008). Similar effects were reported for suppression of TGF in 
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pressure-overload hearts (Lucas et al., 2010), stressing the importance of TGF in promoting 
collagen deposition. As noted earlier, balanced ECM production and degradation is essential, 
and inappropriate accumulation of collagen leads to cardiac fibrosis. TGF has been shown 
to be critical in cardiac fibrosis in various experimental models (Lijnen et al., 2000), and 
inhibition of TGF in such models prevents fibrosis (Teekakirikul et al., 2010). Myocardial 
overexpression of TGF1 induces atrial, but not ventricular fibrosis (Nakajima et al., 2000; 
Verheule et al., 2004). Possibly, this remarkable difference in fibrotic response between atria 
and ventricles is caused by the abundance of CCN2 in atria, which may enhance the effects of 
TGF (Daniels et al., 2009).  
          After MI, CF differentiate to myofibroblasts which exhibit increased fibrillar collagen 
synthesis, SMA expression and capacity to contract their surrounding ECM. Both Ang II 
and TGF1 induce fibroblast-to-myofibroblast differentiation (Swaney et al., 2005), and are 
potent stimulators of collagen production (Butt et al., 1995; Lijnen et al., 2000; Chua et al., 
1991; Eghbali et al., 1991; Swaney et al., 2005). The effects of Ang II and TGF may be 
related as Ang II can induce TGF, and both are involved in an integrated signaling network 
promoting cardiac remodeling (Leask, 2010; Rosenkranz, 2004). The contraction of ECM by 
cardiac myofibroblasts is an important process in wound healing, and can be studied in vitro 
by culturing cells in 3D collagen gels. Both Ang II and TGF enhance in vitro collagen gel 
contraction by CF (Burgess et al., 1994; Drobic et al., 2007; Lijnen et al., 2003). 
      Collectively, these studies on the effects of profibrotic stimuli on CF provide strong 
evidence for differentiation toward myofibroblasts, increased collagen production and 
enhanced contractile behavior. TGF may be the most important driving factor for 
myofibroblast differentiation and ECM synthesis, but interaction and synergy with other 
factors (e.g. CCN2) may be essential in infarct healing and in post-MI fibrosis. See Fig. 2 for 
summary. 
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3.3. Interaction between proinflammatory and profibrotic stimuli 
During the MI healing process, CF are exposed to various autocrine and paracrine signals, the 
strength and composition of which changes with time after the initial insult. As outlined 
above, initially proinflammatory signaling prevails. In the granulation and maturation phase 
of infarct healing, anti-inflammatory/profibrotic factors become more important and lead to 
suppression of inflammatory mediators and ECM remodeling toward a matured scar tissue. 
The mechanisms of interaction between the various factors in the different phases of infarct 
healing are poorly understood, but it is apparent that some of the factors have opposing 
effects on CF biology (Siwik and Colucci, 2004). For example, IL-1 and TNF inhibited 
collagen synthesis in CF, and thus opposed the action of TGF (Siwik et al., 2000). 
Moreover, IL-1 or TNF inhibited basal or TGF-induced expression of the profibrotic 
matricellular protein CCN2 in human (Abraham et al., 2000; Nowinski et al., 2002) or mouse 
(Yu et al., 2009) fibroblasts of non-cardiac origin, results that we have since confirmed with 
IL-1 in human CF (Turner, unpublished data 2011).  
       Surprisingly few studies have been performed to unravel the effect of combinations of 
cytokines and growth factors on CF function. The net effect of IL-1 and TGF1 on adult rat 
CF function was studied by Brown and colleagues, who demonstrated that TGF1 could 
inhibit IL-1-induced MMP-2, -3 and -9 activity and cell migration (Brown et al., 2007). 
Importantly, TGF on its own had no effect on these parameters. TGF1 was also reported to 
prevent CF proliferation in response to the IL-6 family cytokine cardiotrophin-1 (CT-1) 
(Drobic et al., 2007). TGF1 and CT-1 had opposing effects when tested individually, but in 
combination TGF1-mediated effects superseded those of CT-1. TGF-induced collagen gel 
contraction was also inhibited by CT-1 (Drobic et al., 2007). Further evidence for the 
counterbalancing effects of proinflammatory cytokines and profibrotic cytokines comes from 
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studies using fibroblasts of non-cardiac origin. For example, IL-1-induced apoptosis in 
corneal myofibroblasts was prevented by TGF1 (Kaur et al., 2009). In a co-culture of 
keratinocytes and dermal fibroblasts, TGF-mediated SMA induction was suppressed by 
IL-1 (Shephard et al., 2004). Moreover, blocking the IL-1 receptor potentiated SMA 
expression in the fibroblasts, indicating an inhibitory effect of IL-1 on TGF-induced 
myofibroblast differentiation (Shephard et al., 2004). If extrapolation of these data to the MI 
area is permitted, this would imply that during the early phase following ischemia when pro-
inflammatory cytokines are abundant, cardiac myofibroblast differentiation and ECM 
deposition is hampered (summarized in Fig. 2).  
 Aside from opposing effects of proinflammatory and profibrotic factors, synergistic 
upregulation of MMP-9 by IL-1 and either PDGF or bFGF was reported in dermal 
fibroblasts (Bond et al., 1998). If such synergy also exists in the myocardial infarct, this 
might have an important role in ECM degradation during the infarct remodeling.   
 The studies on the effect of combinations of pro-inflammatory and pro-fibrotic factors 
in CF are still very limited in number and suggest that the relative abundance, activity, 
balance and interactions between these factors are pivotal in determining the outcome of the 
different phases of wound healing following MI.  
 
4. Conclusions 
The remodeling events that occur following myocardial damage are clearly complex and 
regulated by temporal and spatial fluctuations in key bioactive molecules, many of which 
influence CF function or are derived from the CF themselves. In vitro cell culture studies 
have proved useful in characterizing CF responses to individual cytokines and growth factors, 
and limited evidence is available on how certain combinations of molecules act to modulate 
CF function. However, more studies are clearly warranted to more accurately define the net 
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functional effects of multiple stimuli at the level of the CF, in order to more precisely model 
the in vivo scenario. By understanding the interplay between inflammatory and fibrotic 
signals at the level of individual myocardial cell types, we hope to develop effective therapies 
that protect essential repair processes post-MI, whilst reducing pathological remodeling.  
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FIGURE LEGENDS 
Fig. 1. The main phases of post-MI myocardial remodeling. Abbreviations: CF, cardiac 
fibroblast; CMF, cardiac myofibroblast; ECM, extracellular matrix; GF, growth factor; MMP, 
matrix metalloproteinase. 
 
Fig. 2. The central role of cardiac fibroblasts in responding to proinflammatory and 
profibrotic signals. See main text for details. Myocardial infarction causes damage and death 
of myocytes with subsequent production of damage-associated molecular patterns (DAMPs); 
molecules that trigger an acute inflammatory response. CF respond by undergoing migration, 
proliferation and increased expression of proinflammatory cytokines, chemokines and 
MMPs. Subsequently in the granulation phase, profibrotic stimuli (e.g. TGF, PDGF etc) 
induce CF to differentiate to a myofibroblast phenotype with increased SMA expression, 
increased expression of pro-fibrotic factors (e.g. CCN2/CTGF) and enhanced collagen 
secretion. In the maturation phase, myofibroblasts continue to synthesize ECM proteins and 
contract the wound area. The relative amounts of proinflammatory and profibrotic stimuli 
fluctuate at different stages of the post-MI remodeling process, and there is increasing 
evidence that these two types of stimuli have opposing effects on CF function.  
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